XORTX Announces “Fireside Chat” with XORTX CEO
June 21 2022 - 7:00AM
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX |
TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical
company focused on developing innovative therapies to treat
progressive kidney disease, is pleased to announce that on June 22,
2022 at 11am EST, Dr. Allen Davidoff, XORTX’s CEO, will host a
“Fireside Chat” that will include a presentation “Exciting
Developments in New Therapies for Progressive Kidney Diseases” that
outlines the Company’s therapies, progress to date, planned future
regulatory and clinical activities and to answer questions from
investors and potential investors.
Private investors and institutions may register
utilizing the following link: XORTX “Fireside Chat” with
CEO Allen W. Davidoff, PhD June 22 AT 11am
EST.
About XORTX Therapeutics
Inc.
XORTX is a pharmaceutical company with two
clinically advanced products in development – XRx-008 for Autosomal
Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute
kidney and other acute organ injury associated with Coronavirus /
COVID-19 infection and XRx-225 is a pre-clinical stage program for
Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its
clinical development stage products that target aberrant purine
metabolism and xanthine oxidase to decrease or inhibit production
of uric acid. At XORTX, we are dedicated to developing medications
to improve the quality of life and future health of patients.
Additional information on XORTX is available at www.xortx.com.
For further information, please contact:
Allen
Davidoff, CEO |
Nick
Rigopulos, Director of Communications |
adavidoff@xortx.com or +1 403 455 7727 |
nick@alpineequityadv.com or +1 617 901 0785 |
The TSX Venture Exchange and Nasdaq have neither
approved nor disapproved the contents of this news release. No
stock exchange, securities commission or other regulatory authority
has approved or disapproved the information contained herein.
Forward Looking Statements
This press release may contain express or
implied forward-looking statements pursuant to Canadian and U.S.
Federal securities laws. These forward-looking statements and their
implications are based on the current reasonable expectations of
the management of XORTX only, and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in such forward-looking statements.
Except as otherwise required by law, XORTX undertakes no obligation
to publicly release any revisions or updates to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. More detailed information about the risks and uncertainties
affecting XORTX is contained in the Company’s most recently filed
Annual Information Form and the Management Discussion and Analysis
for its most recent financial reporting period filed on the
Company’s SEDAR profile (www.sedar.com) and under the heading “Risk
Factors” in XORTX’s Registration Statement on Form F-1 filed with
the Securities and Exchange Commission (“SEC”) available on the
SEC's website, www.sec.gov.
XORTX Therapeutics (NASDAQ:XRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
XORTX Therapeutics (NASDAQ:XRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024